BHV-1300 reduced total IgG by up to 84% in a four-week Phase 1 study. The treatment was well-tolerated, with no serious adverse events reported. Get access to the leaderboards pointing to tomorrow’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results